Advertisement
Advertisement
U.S. markets open in 7 hours 33 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Organovo Holdings, Inc. (ONVO)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.5100+0.0400 (+2.72%)
At close: 03:59PM EST
1.4700 -0.04 (-2.65%)
After hours: 04:07PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4700
Open1.4800
Bid0.0000 x 800
Ask0.0000 x 1300
Day's Range1.4700 - 1.5500
52 Week Range1.4500 - 5.2000
Volume13,868
Avg. Volume72,839
Market Cap13.157M
Beta (5Y Monthly)1.04
PE Ratio (TTM)N/A
EPS (TTM)-1.3150
Earnings DateFeb 08, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ONVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Organovo Holdings, Inc.
    Daily – Vickers Top Buyers & Sellers for 11/30/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    19 hours agoArgus Research
View more
  • GlobeNewswire

    Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

    SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a three-dimensional biology (3D biology) company focused on delivering scientific and medical breakthroughs using novel technologies including 3D bioprinting, today announced that it has successfully advanced the use of its first inflammatory bowel disease (IBD) model and has achieved the next milestone, target validation. The company announced in May 2022 that it had achieved a successful Crohn’s disease model

  • GlobeNewswire

    Organovo to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease, today announced that Keith Murphy, Executive Chairman, will participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12 - 14, 2022. Organovo plans to advance drugs discovered in its cutting-edge human 3D disease models in inflammatory bowel dis

  • GlobeNewswire

    Organovo Announces Postponement of Annual Meeting of Stockholders

    SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), an early-stage biotechnology company that is focusing on building high fidelity, 3D tissues that recapitulate key aspects of human disease (the “Company”), today announced that its 2022 Annual Meeting of Stockholders (the “2022 Annual Meeting”) that was scheduled to be held at 9:00AM (Pacific Time) on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM (Pacific Time), a date determined

Advertisement
Advertisement